Lanreotide peptide was labeled with
153Sm-H
1ETA and
188Re-MAG
3 in order to evaluate whether or not their conjugation to the peptide produce significant differences of the in vitro lipophilicity with respect to the
188Re-lanreotide prepared by the direct labeling method (highly lipophilic). The differences of lipophilicity between the complexes, were evaluated using a reverse phase HPLC system. The measured lipophilicity of
153Sm-H
1ETA-lanreotide,
188Re-MAG
3-lanreotide and
188Re-lanreotide was taken to be the capacity factor [
k" = (
t
R-
t
0)/
t
0 where
t
R is the retention time and
t
0 is the dead time] for each of the complexes under identical chromatography conditions. Results showed that the in vitro lipophilicity decreased in the order
188Re-lanreotide (direct labeling),
188Re-MAG
3-lanreotide and
153Sm-H
1ETA-lanreotide. Since the last one has a capacity factor (
k") similar to that of
188Re-MAG
3, some renal elimination for
153Sm-H
1ETA-lanreotide could be expected, which probably would reduce the unnecessary radiation dose to normal tissues.
相似文献